Opinion|Videos|April 10, 2024
Emerging Treatments for Myelofibrosis
Andrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, conclude that the increasing complexity in myelofibrosis treatment options, including multiple JAK inhibitors and emerging combination therapies, signals an exciting era of individualized care, yet underscores the need for reevaluating study end points to enhance patient outcomes further.
Advertisement
Episodes in this series
Advertisement
Related to this article
The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.
The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
The oral PLK1 inhibitor onvansertib received FDA orphan drug designation in CMML.
Advertisement
Advertisement
Trending on OncLive
1
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
2
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
3
T-DXd Gains EU Approval in Residual HER2+ Early Breast Cancer
4
Basser Center for BRCA Awards 2026 Global Prize to Judy Garber
5